Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Targeting the GPX4-FUNDC1 Interaction with Magnesium Lithospermate B Attenuates Sepsis-Associated Lung Injury.

Li Z., Liu C., Ma Z., Zheng D., Wang R., Yu Y.

Animal Study on Chronic Inflammation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Sci (Weinh) (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41616122
PMCID
PMC13067869
DOI
10.1002/advs.202516488

Abstract (original English)

Sepsis-associated lung injury (SALI) remains a critical clinical challenge, partly driven by ferroptosis-induced endothelial dysfunction. The pathological interaction between FUN14 domain-containing protein 1 (FUNDC1) and glutathione peroxidase 4 (GPX4) promotes ferroptosis and disrupts mitophagic flux. Magnesium lithospermate B (MLB), an active compound derived from Salvia miltiorrhiza, possesses anti-inflammatory and antioxidant properties and exhibits potential for vascular protection. Here, it is demonstrated that MLB mitigates sepsis-associated pulmonary vascular injury by suppressing ferroptosis and restoring mitochondrial homeostasis. Mechanistically, MLB directly binds GPX4 at Gly79, thereby disrupting the GPX4-FUNDC1 interaction, stabilizing GPX4 enzymatic activity, and preventing its FUNDC1-mediated mitophagic degradation. To enhance pulmonary targeting, P-selectin-binding peptide-engineered adipose-derived stem cell extracellular vesicles were constructed to deliver MLB, substantially improving its therapeutic efficacy in SALI. Furthermore, a silver-citrate nanostructure-based surface-enhanced Raman spectroscopy platform was developed, enabling precise identification of MLB's Raman fingerprint spectrum with nanogram-level sensitivity and time-resolved in vivo biodistribution profiling. Collectively, these findings reveal a novel therapeutic mechanism and efficacy of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsSepsisPhospholipid Hydroperoxide Glutathione PeroxidaseDrugs, Chinese HerbalMiceLung InjuryMitochondrial ProteinsHumansFerroptosisMembrane Proteins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research